Rapilin™

Basalin® is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin® is able to stablely control human blood sugar within 24...

GanleeFine™ is pen needle for single use, collaborately used with insulin pen or prefilled pen for insulin injection. GanleeFine™ has 5 specifications including 0.30x6mm/30G, 0.30x8mm/30G, 0.25x6mm/31G, 0.25x8mm/31G and 0.23x4mm/32G, which can meet different people's injection needs.

GanleePen is a reusable insulin pen produced by Gan & Lee's wholly-owned subsidiary, Gangan Medical Technology Co., Ltd. It has user-friendly design, big dose window, precise dose and clear reminder for dose adjustment. In addition, GanleePen is made of high-quality and reusable materials. The color of...

Prandilin® is an insulin lispro injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2007. As a fast-acting biosimilar insulin, Prandilin® is able to rapidly control human blood sugar 15-20mins after injection before a meal for the treatment of d...

Prandilin®25 is a premix insulin lispro suspension developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2014. As a fast-acting biosimilar insulin, Prandilin®25 is able to rapidly and stablely control human blood sugar 15-20mins after injection before a mea...

Gai Liu, Director at Gan & Lee Pharmaceuticals, shares the company’s remarkable journey, highlighting key milestones, their diverse product portfolio, and ongoing research initiatives. The interview also provides insights into Gan & Lee's international expansion strategies, talent development, and innovative approaches to staying competitive in the global pharmaceutical landscape.